The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis
Current Oncology · 05.09.2025 · 32 (9) · 496
DOI: 10.3390/curroncol32090496 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 05.09.2025. Verfasst von Christopher Sherry und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Receptors, Interleukin-8B, Receptors, Interleukin-8A, Interleukin-8. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institiute of Health (NIH), Cancer Center Support Grant.
Abstract (Originalsprache)
Peritoneal carcinomatosis (PC) is a late-stage manifestation of abdominopelvic malignancies with poor prognosis and limited treatment options. Unique biochemical mechanisms within the peritoneal cavity play a key role in disease progression and resistance to therapy. Despite current therapies like systemic chemotherapy and cytoreductive surgery, patients frequently develop severe complications, including bowel obstruction, nutritional decline, and ascites, driving the need to address the pro-tumorigenic niche in the peritoneal cavity. The immune microenvironment in PC is marked by elevated proinflammatory mediators, such as IL-6 and IL-8, which skew the response toward innate rather than adaptive immune responses. IL-8 signaling, through its receptors CXCR1 and CXCR2, promotes neutrophil recruitment, chronic inflammation, angiogenesis, epithelial–mesenchymal transition, and immune evasion, making the IL-8/CXCR1/CXCR2 axis a potential therapeutic target in PC. Pre-clinical models provide evidence that IL-8 or CXCR1/CXCR2 blockade may be a valuable therapeutic strategy. IL-8 targeting agents such as monoclonal antibodies (BMS-986253) and small-molecule inhibitors (SX-682, AZD5069, navarixin) have shown efficacy in mitigating tumor growth and improving the efficacy of immune checkpoint inhibitors. Phase I and II trials have demonstrated encouraging safety profiles and preliminary efficacy when treating multiple abdominopelvic malignancies. In this review, we discuss the influence of the IL-8/CXCR1/CXCR2 axis within the peritoneal immune environment in PC and highlight recent work using IL-8 or CXCR1/CXCR2 blockade as a therapeutic strategy for PC. Continued research into the peritoneal immune microenvironment and the development of targeted therapies are essential for improving the management and prognosis of PC, potentially enhancing antitumor immunity and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA.
- Department of Cardiothoracic Surgery Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA.
- Department of Medicine, Drexel University School of Medicine, Philadelphia, PA 19104, USA.
ORCID-Profile: Neda Dadgar, Zuqiang Liu, Kunhong Xiao, Ali H Zaidi, Albert D Donnenberg, David L Bartlett, Patrick L Wagner
Förderung
- NCI NIH HHS
- National Institiute of Health (NIH)
- Cancer Center Support Grant
- Department of defense, MetaVivor 713943, The Pennsylvania Breast Cancer Coalition, The Glimmer of Hope Foundation, and the David Downing Fund
- National Institute of Health (NIH)
- The Pennsylvania Breast Cancer Coalition, the Glimmer of Hope Foundation, and the David Downing Fund
Zitieren
APA
Sherry, C., Dadgar, N., Liu, Z., Fan, Y., Xiao, K., Zaidi, A. H., Donnenberg, V. S., Donnenberg, A. D., Bartlett, D. L., & Wagner, P. L. (2025). The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis. Current Oncology, 32(9), 496. https://doi.org/10.3390/curroncol32090496
Vancouver
Sherry C, Dadgar N, Liu Z, Fan Y, Xiao K, Zaidi AH, et al. The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis. Current Oncology. 2025;32(9):496. doi:10.3390/curroncol32090496
BibTeX
@article{Sherry2025,
author = {Sherry, Christopher and Dadgar, Neda and Liu, Zuqiang and Fan, Yong and Xiao, Kunhong and Zaidi, Ali H and Donnenberg, Vera S and Donnenberg, Albert D and Bartlett, David L and Wagner, Patrick L},
title = {The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {9},
pages = {496},
doi = {10.3390/curroncol32090496}
}
EUVIMED